Endocyte to cut workforce 40%

Monday, June 5, 2017

Endocyte, a provider developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, announced updates on clinical development for EC1456, its folate receptor-targeted tubulysin cancer therapy, and EC1169, its prostate-specific membrane antigen targeted (PSMA-targeted) tubulysin prostate cancer therapy.

[Read More]

David Meek appointed Ipsen’s chief executive officer

Monday, July 11, 2016

The board of directors of Ipsen appointed David Meek as chief executive officer, effective July 18, 2016. On this date, Marc de Garidel will assume the role of non-executive chairman and will continue to serve the board of directors through his deep industry expertise. In addition, Marc de Garidel will advise Mayroy, the Ipsen controlling holding company.

[Read More]